Furoxanopyrimidines as exogenous donors of nitric oxide

Pharmaceutical Chemistry Journal

Volumn 36, Issue 10, 2002, Pages 523-527

  Granik, V G ^a   Kaminka, M E ^a   Grigor'ev, N B ^a   Severina, I S ^a   Kalinkina, M A ^b   Makarov, V A ^b   Levina, V I ^c  

^a Organic Intermediates and Dyes Institute   (Russian Federation)

^b ZAO Institute of Pharmaceutical Technologies   (Russian Federation)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYANO 4 AMINO 1,2,5 OXADIAZOLE 2 OXIDE; 3,12 BIS[(OXODIAZOLO[4,3 D]PYRIDIMID 9 YL) 1 OXIDE] 3,12 DIAZA 6,9 DIAZONIADISPIRO[5.2.5.2]HEXADECANE DICHLORIDE; 7 (4 BENZOYLPIPERAZINO)OXODIAZOLO[4,3 D]PYRIMIDINE 1 OXIDE; 7 DIMETHYLAMINOOXODIAZOLO[4,3 D]PYRIMIDINE 1 OXIDE; FURAZOLIDONE; FUROXANOPYRIMIDINE DERIVATIVE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; MOLSIDOMINE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; ELECTROCHEMICAL DETECTION; EXPERIMENTATION; HYPERTENSION; IN VITRO STUDY; LD 50; MALE; NONHUMAN; RAT; SPASMOLYSIS; VASODILATATION;

EID: 0037741773     PISSN: 0091150X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022446208137     Document Type: Article

References (18)

1. V. G. Granik, S. Yu. Ryabova, and N. B. Grigor'ev, Usp. Khim., 66(8), 792-816 (1997).
2. M. Feelish, J. Cardiovasc. Pharmacol., 17 (Suppl. 3), 25-31 (1991).
3. K. Schonafinger, Farmaco, 54, 316-319 (1999).
4. M. Feelish, K. Schonafinger, and E. Noak, Biochem. Pharmacol., 44, 1149-1157 (1992).
5. C. Medana, G. Ermondi, R. Fruttero, et al., J. Med. Chem., 37, 1-8 (1994).
6. O. G. Busygina, N. V. Pyatakova, Yu. V. Khropov, et al., Biokhimiya, 65(4), 540-546 (2000).
7. R. Ferreoli, G. C. Folco, A. Ferretti, et al., Br. J. Pharmacol., 114, 816-823 (1995).
8. H. Bohn, J. Brendel, P. A. Martorana and K. Schonafinger, Br. J. Pharmacol., 114, 1605-1608 (1995).
9. J. R. Prous (ed.), Annual Drug Data Rep., 16(6), 551 (1994).
10. J. R. Prous (ed.), Annual Drug Data Rep., 21(90), 787 (1999).
11. J. R. Prous (ed.), Annual Drug Data Rep., 20(5), 404 (1998).
12. V. K. Makarov, A. L. Sedov, O. S. Anisimova, and V. G. Granik, Khim. Geterotsikl. Soedin., No. 6, 811-814 (1996).
13. F. L. Rose, J. Am. Chem. Soc., 4116-4123 (1954).
14. V. A. Makarov, A. L. Sedov, M. P. Nemeryuk, and T. S. Safonova, Khim. Geterotsikl. Soedin., No. 10, 971-974 (1994).
15. H. Bohn, J. Brendel, P. A. Bartorana, and K. Schonafinger, Br. J. Pharmacol., 114, 1605-1612 (1995).
16. A. Di Stilo, G. Sorba, and C. Medana, Farmaco, 52(5), 339-341 (1997).
17. Y. Kobayashi, K. Ikeda, K. Shinozuka, et al., Clin. Exp. Pharm. Physiol., 18, 397-399 (1991).
18. R. D. Bunag, Handbook of Hypertension, Vol. 4 (1984).